SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended	3 Months Ended		9 Months Ended				0 Months Ended	1 Months Ended	6 Months Ended
	Sep. 30, 2009	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Protalix Bio Therapeutics Incorporation [Member]	Sep. 30, 2013 Pfizer Incorporation [Member]	Jun. 18, 2013 Protalix Ltd. [Member]	Sep. 30, 2009 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Jun. 30, 2012 Upon FDA Approval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries				2
Pfizer Agreement, upfront payment received	$ 60,000								$ 5,000
Milestone payment triggered										25,000
Pfizer Agreement, future revenues and expense sharing percentage						40.00%	60.00%
Supply commitment for entitled rights to be received								280,000
License and supply agreement potential future payment								12,500
Supply commitment per year								$ 40,000
Common stock, par value per share		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive		8,817,090	7,508,240	7,879,601	7,169,035